The Prognostic Role of CDK9 in Bladder Cancer

• Published in: Cancers 2022-03, Vol.14 (6), p.1492
• Main Authors: Borowczak, Jędrzej, Szczerbowski, Krzysztof, Maniewski, Mateusz, Zdrenka, Marek, Słupski, Piotr, Antosik, Paulina, Kołodziejska, Sylwia, Sekielska-Domanowska, Marta, Dubiel, Mariusz, Bodnar, Magdalena, Szylberg, Łukasz
• Format: Article
• Language: English
• Subjects: Antibodies; Apoptosis; Bladder cancer; Cyclin-dependent kinase; Cyclin-dependent kinase 9; Cyclin-dependent kinases; DNA repair; Genomic instability; Kinases; Lymphatic system; Medical prognosis; Metastasis; Multivariate analysis; Prognosis; RNA polymerase; Statistical analysis; Transcriptomics; Tumors; Urothelial cancer; Urothelial carcinoma
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14061492

Introduction: Most patients with urothelial carcinoma are diagnosed with non-invasive tumors, but the prognosis worsens with the progression of the disease. Overexpression of cyclin-dependent kinase 9 has been recently linked to increased cancer proliferation, faster progression, and worse prognosis. However, some cancers seem to contradict this rule. In this work, we explored the prognostic role of CDK9 expression in urothelial carcinoma. Materials and Methods: We performed immunohistochemical analysis on 72 bladder cancer samples. To assess a larger group of patients, the Cancer Genome Atlas (TCGA) database containing 406 cases and transcriptomics information through the Human Pathology Atlas were analyzed. Results: CDK9 is overexpressed in urothelial cancer tissues when compared to normal urothelial tissues (p < 0.05). High CDK9 expression was observed in low-stage, low-grade, and non-muscle-invasive tumors (p < 0.05). The patients with high CDK9 expression had a significantly higher 5-year overall survival rate than those with low CDK9 expression (77.54% vs. 53.6% in the TMA group and 57.75% vs. 35.44% in the TCGA group, respectively) (p < 0.05). The results were consistent in both cohorts. Multivariate Cox regression analysis indicated that low CDK9 status was an independent predictor for poor prognosis in the TCGA cohort (HR 1.60, CL95% 1.1−2.33, p = 0.014). Conclusions: High CDK9 expression predicts a favorable prognosis in urothelial carcinoma and is associated with clinicopathological features characteristic for early-stage disease. The decrease in CDK9 expression can be associated with the build-up of genetic instability and may indicate a key role for CDK9 in the early stages of urothelial carcinoma.